This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Breast유방의 악성신생물 (유방암)

Classification codesC50 (ICD-10) — C50.0 nipple, C50.1 central portion of breast, C50.2 upper-inner quadrant, C50.3 lower-inner quadrant, C50.4 upper-outer quadrant (most common), C50.5 lower-outer, C50.6 axillary tail, C50.8 overlapping, C50.9 unspecified
SynonymsBreast cancer, invasive breast carcinoma, triple-negative breast cancer (TNBC), HER2-positive breast cancer, hormone receptor-positive breast cancer, ductal carcinoma in situ of the breast (DCIS)
Adult onsetVery high — the most common cancer in Korean women (excluding thyroid cancer); peaks at ages 45–54; frequency increases from the 30s
Special Copayment ReductionV193 — 5 years from the date of cancer patient registration, copayment 5%
1. HistoryImhotep papyrus (2600 BC), Halsted radical mastectomy (1894), tamoxifen (1977), discovery of BRCA1/2 (1994/1995)
2. CausesBRCA1/2 mutations, estrogen exposure, age, obesity, alcohol, radiation, family history
3. GeneticsBRCA1/2/PALB2/CHEK2/ATM/TP53/PIK3CA/HER2/CDH1; molecular subtypes (Luminal/HER2+/TNBC)
4. EpidemiologyMost common cancer in Korean women (ASR 55.6); screening rate 70.6% in 2024; increasing early stage at diagnosis
5. PathophysiologyEstrogen-driven cell proliferation→DNA damage→multistep carcinogenesis; BRCA loss→homologous recombination deficiency
6. SymptomsPainless breast mass, nipple discharge, skin changes (peau d'orange), breast asymmetry
7. SignsHard mass, axillary lymphadenopathy, skin fixation, nipple retraction
8. ScreeningNational cancer screening mammography every 2 years (ages 40–69), combined ultrasound, criteria for BRCA genetic testing
9. DiagnosisMammography/ultrasound/MRI/core needle biopsy/ER·PR·HER2·Ki-67/BRCA testing
10. TreatmentBreast-conserving surgery/mastectomy+sentinel lymph node/chemotherapy/endocrine (tamoxifen·AI)/CDK4/6i/HER2-targeted/PARP inhibition/immunotherapy
11. PrognosisKorean 5-year survival rate for stage I–II >90%; prognostic differences by molecular subtype; TNBC poor
12. PreventionBreast self-examination, regular mammography, prophylactic surgery/chemoprevention for BRCA carriers
13. ReferencesKey references

1. History

Breast cancer is one of the longest-described cancers in human history. The Egyptian Imhotep papyrus (about 2600 BC) contains a description of "bulging tumors of the breast (ulcer of the breast)" and records that there was no treatment for it. In ancient Greece, Hippocrates (BC 460–370) explained breast tumors as an excess of black bile, and Galen (130–200 AD) systematically described breast cancer and recommended surgery.

The milestone of modern breast cancer treatment is the Halsted radical mastectomy, introduced by William Stewart Halsted in 1894. This operation, which removes the breast, pectoralis major, pectoralis minor, and axillary lymph nodes, remained the standard until the mid-20th century. In the 1970s–1980s, NSABP (National Surgical Adjuvant Breast and Bowel Project) studies led by Bernard Fisher demonstrated that breast-conserving surgery achieves survival equivalent to radical mastectomy.

In the history of endocrine therapy, George Beatson first observed remission of breast cancer with oophorectomy in 1896, and the subsequent discovery of the estrogen receptor (ER) (Elwood Jensen, 1958) and the clinical application of tamoxifen (1970s) became the foundation of endocrine therapy for breast cancer. In genetics, the BRCA1 gene (Mary-Claire King) was discovered in 1994 and the BRCA2 gene in 1995, elucidating the molecular mechanism of hereditary breast cancer. Since the 2000s, HER2-targeted therapy, led by trastuzumab (FDA approval 1998), has been introduced and dramatically improved the prognosis of HER2-positive breast cancer. In Korea, since mammography was introduced into the National Cancer Screening Program in 2002, the screening rate had risen to 70.6% as of 2024.

2. Causes

Breast cancer arises from a complex interaction of genetic factors and environmental and lifestyle factors.

Genetic factors

Reproductive and endocrine factors

Lifestyle factors

3. Genetics

The breast cancer genome is highly heterogeneous, and treatment approaches differ by molecular subtype.

Major driver genes

GeneType of alterationClinical significance
BRCA1/BRCA2Germline/somatic mutationHomologous recombination deficiency (HRD); PARP inhibitor sensitivity
PALB2Germline mutationInteracts with BRCA2; HRD; consider PARP inhibitors
PIK3CASomatic mutation (about 35%)Common in ER+ breast cancer; target of alpelisib
HER2(ERBB2)Amplification/overexpression (about 15–20%)Target of trastuzumab, pertuzumab, T-DM1, T-DXd
TP53MutationCommon in TNBC (about 80%); poor prognosis
CDH1(E-cadherin)Mutation/lossSpecific to lobular breast cancer; associated with hereditary diffuse gastric cancer

Molecular subtype classification

Breast cancer is classified into four main molecular subtypes according to gene expression patterns.

Pharmacogenomics

CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) have been established as the standard treatment for HR+/HER2- advanced breast cancer. PARP inhibitors (olaparib, talazoparib) have demonstrated efficacy in HR-/HER2- breast cancer with germline BRCA1/2 mutations (OlympiA trial). The concepts of HER2-low and HER2-ultralow have been introduced into clinical practice with the expanded indications of T-DXd (trastuzumab deruxtecan) (DESTINY-Breast06, 2024).

4. General epidemiology

Breast cancer is the most common cancer in Korean women excluding thyroid cancer; according to 2023 Korean cancer statistics, its age-standardized incidence rate (ASR) was 55.6 (per 100,000 population), ranking first among cancers in women. It is also the 5th leading cause of cancer death (ASR 5.5). Unlike in Western countries, the pattern of breast cancer incidence in Korea has shown a peak at ages 45–54 followed by a decline, but recently incidence has also been increasing in those aged 60 and older.

The Korean National Cancer Screening Program (KNCSP) introduced biennial mammography screening for women aged 40 and older in 2002, and the screening rate rose sharply from 38.4% in 2005 to 70.6% in 2024. As a result, the proportion of localized-stage (early) diagnoses increased from 60.3% in 2005 to 71.8% in 2023. The 5-year relative survival rate is 93.3% (Korea, 2017–2021), one of the highest in the world. Male breast cancer is very rare, accounting for less than about 1% of all breast cancers.

5. Pathophysiology

The pathogenesis of breast cancer varies by molecular subtype, and the best understood is the estrogen-driven carcinogenic pathway.

Estrogen-driven carcinogenesis (Luminal type)

Estrogen binds to the estrogen receptor (ER-α) and promotes proliferation of breast epithelial cells. During continuous cell proliferation and DNA replication, DNA damage from oxidative metabolites accumulates. As additional molecular events accumulate, such as PIK3CA mutations (PI3K pathway activation), CCND1 amplification (CDK4/6 hyperactivation), and ESR1 mutations (endocrine therapy resistance), the disease progresses to invasive breast cancer.

BRCA-related carcinogenesis

BRCA1/BRCA2 proteins play a key role in homologous recombination (HR) repair of DNA double-strand breaks. When loss of BRCA1/2 function causes homologous recombination deficiency (HRD), DNA damage cannot be repaired and genomic instability worsens. This leads mainly to ER- basal-like breast cancer and explains the high sensitivity to PARP inhibitors.

HER2 overexpression carcinogenesis

HER2 gene amplification and protein overexpression cause sustained activation of the PI3K/AKT/mTOR and RAS/MAPK pathways via HER2/HER3 heterodimers, promoting cell proliferation, survival, and metastasis.

6. Symptoms

Breast cancer is often asymptomatic in the early stage, and an increasing number of cases are found through screening.

Symptoms related to the primary breast tumor

Symptoms related to metastasis

7. Signs

The main clinical signs suggestive of breast cancer on physical examination are as follows.

8. Screening

Korean National Cancer Screening Program

The standard of Korean national cancer screening is mammography every 2 years for women aged 40–69. It is provided free of charge through the National Health Insurance Service. Mammography is known to increase the proportion of breast cancers detected at an early stage and to reduce breast cancer mortality by about 15–20%.

Additional test methods

Criteria for BRCA genetic testing

BRCA1/BRCA2 genetic testing is recommended if one or more of the following apply: a strong family history of breast or ovarian cancer, breast cancer diagnosed before age 40, triple-negative breast cancer (before age 60), bilateral breast cancer, male breast cancer, or simultaneous diagnosis of breast and ovarian cancer. In Korea, the criteria for BRCA testing covered by National Health Insurance are specified.

9. Diagnosis

The diagnosis of breast cancer is made by a triple approach of radiology, histopathology, and molecular pathology.

Imaging tests

Histopathological diagnosis

Staging

The AJCC 8th edition TNM staging system is used, and in addition to tumor size (T), lymph node status (N), and distant metastasis (M), a Prognostic Stage integrating prognostic factors such as ER/PR/HER2, tumor grade, and the Oncotype DX recurrence score is used.

10. Treatment

The standard for breast cancer treatment is a highly personalized multidisciplinary approach according to stage, molecular subtype, and patient characteristics.

Surgical treatment

Adjuvant chemotherapy

Endocrine therapy

HER2-targeted therapy

PARP inhibitors and immunotherapy

11. Prognosis

Stage / subtypeKorean 5-year survival rate
Overall 5-year relative survival rate (Korea 2017-2021)93.3%
Stage I>97%
Stage IIAbout 88–92%
Stage IIIAbout 70–80%
Stage IV (metastatic)About 29%
Luminal AMost favorable; 10-year survival rate 80–90%
HER2-positive (trastuzumab era)Greatly improved; 5-year survival rate about 85–90% (early)
Triple-negative (TNBC)5-year survival rate about 77% (early); worst when metastatic

Molecular subtype has the most important effect on prognosis, and Ki-67, tumor grade, lymph node status, and tumor size are also important prognostic factors. The higher the Oncotype DX Recurrence Score, the greater the benefit of chemotherapy and the worse the prognosis. With the recent introduction of CDK4/6 inhibitors, T-DXd, PARP inhibitors, and others, survival in advanced breast cancer continues to improve.

12. Prevention

Participation in screening

Lifestyle modification

Risk-reduction strategies for BRCA carriers

13. References

  1. Cancer Statistics in Korea 2023. Cancer Res Treat. 2025. PMC13093029.
  2. Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality. NPJ Breast Cancer. 2021. PMC8238931.
  3. Trends in Cancer-Screening Rates in Korea. Cancer Res Treat. 2024.
  4. KEYNOTE-522: Pembrolizumab + chemo neoadjuvant/adjuvant for early TNBC. NEJM. 2022.
  5. OlympiA: Olaparib adjuvant for high-risk HER2-negative germline BRCA breast cancer. NEJM. 2021.
  6. DESTINY-Breast06: T-DXd in HER2-low/ultralow metastatic BC. NEJM. 2024.
  7. Diagnosis and treatment of HER2-positive breast cancer. Korean J Med. 2025;100(2):81.
  8. Palbociclib as first-in-class CDK4/CDK6 inhibitor for HR+/HER2- advanced BC. PMC4534142.
  9. Korean Breast Cancer Society. Breast cancer clinical practice recommendations 2023. 2023.
  10. National Cancer Information Center. Breast cancer. 2024.